Safety trial of fecal microbiota transplantation for inflammatory bowel disease
Not Applicable
- Conditions
- Inflammatory bowel disease
- Registration Number
- JPRN-UMIN000020954
- Lead Sponsor
- Department of Gastroenterology, Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Recipient 1) Severe complications in organs including heart, kidney, lung, hematopoiesis, and coagulation system. Severe infectious disease. 2) HIV infection 3) in breast-feeding 4) in pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of fecal microbiota transplantation for inflammatory bowel disease will be assessed in 8 weeks after the treatment according to criteria for adverse events.
- Secondary Outcome Measures
Name Time Method